Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use AREXVY safely and effectively. See full prescribing information for AREXVY. AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) for injectable suspension, for intramuscular useInitial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-other
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: •individuals 60 years of age and older; •individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Limitations of Use AREXVY is not for use in pregnant individuals [see Use in Specific Populations (8.1)].
- generic_name
- respiratory syncytial virus vaccine recombinant, adjuvanted
- brand_name
- respiratory syncytial virus glycoprotein F, AS01
- product_names
- Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted, respiratory syncytial virus glycoprotein F, AS01
- ndc
- 58160-848, 58160-848-11, 58160-723, 58160-723-03, 58160-744, 58160-744-03, 58160-894, 58160-894-15, 58160-719, 58160-719-03, 58160-749, 58160-749-07, 58160-882, 58160-882-12
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en